I don’t like the idea and rather than hype a stock I would prefer that genuine investors do their own research. The value will be recognised in due course and for the right reasons.
I don’t care how much of a sure thing people think they have, nothing is guaranteed in the Biotechnology world. Paul has too much class to feel that he has to help sooth shareholders fears. He does a good job explaining the merits of the company and it’s prospects. There is literally mountains of information and answers to all range of questions regarding PAR (just ask Mozz) for those prepared to do the work.
You are constantly worrying about the short term share price action (while other stocks run) while I am rubbing my hands and adding shares periodically when I can like yesterday. If we had someone constantly placating shareholders whims I simply wouldn’t get that opportunity. PAR runs to the beat of its own drum and not the markets. It’s not for everyone.
The share market is a transfer of wealth from the impatient to the patient and I am one of the most patient investors there is.
Having said that I think the share price will move a lot this year hence why this period of suppressed SP is a golden opportunity for me.
One can get too close to management, as I know I have in the past. Better to just let the companies performance speak for itself and the value in terms of SP appreciation will be eventually realised.
Just IMO and DYOR.
PAR Price at posting:
$2.28 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)